AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

TÉMOZOLOMIDE

11 registrations across 1 African market— 0 active

Markets with TÉMOZOLOMIDE

Recent registrations

Brand / ProductMarketHolderStatusExpires
TEMOZOLOMIDE NEAPOLIS
Gélule / 100 mg
🇹🇳TunisiaNEAPOLIS PHARMAexpiredSept 2022
TEMOZOLOMIDE NEAPOLIS
Gélule / 250 mg
🇹🇳TunisiaNEAPOLIS PHARMAexpiredSept 2022
TEMOZOLOMIDE NEAPOLIS
Gélule / 20 mg
🇹🇳TunisiaNEAPOLIS PHARMAexpiredSept 2022
TEMO
Gélule / 20 mg
🇹🇳TunisiaLINO PHARMAexpiredSept 2021
TEMO
Gélule / 5 mg
🇹🇳TunisiaLINO PHARMAexpiredSept 2021
TEMO
Gélule / 250 mg
🇹🇳TunisiaLINO PHARMAexpiredSept 2021
TEMO
Gélule / 100 mg
🇹🇳TunisiaLINO PHARMAexpiredSept 2021
TEGOZOL
Gélule / 20 mg
🇹🇳TunisiaHIKMA PharmaceuticalsexpiredMar 2020
TEGOZOL
Gélule / 5 mg
🇹🇳TunisiaHIKMA PharmaceuticalsexpiredMar 2020
TEGOZOL
Gélule / 100 mg
🇹🇳TunisiaHIKMA PharmaceuticalsexpiredMar 2020
TEGOZOL
Gélule / 250 mg
🇹🇳TunisiaHIKMA PharmaceuticalsexpiredApr 2017

TÉMOZOLOMIDE in Africa — Regulatory Overview

TÉMOZOLOMIDE is registered across 1 African markets with 11 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia. AfricaRegulatory refreshes this data daily from official government sources.

Of the 11 registrations, 0 (0%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.